long-acting alpha-galactosidase A (HM15421) / Hanmi, GC Biopharma - LARVOL DELTA

A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease (clinicaltrials.gov) - P1/2 | N=18 | Recruiting | Sponsor: GC Biopharma Corp | Not yet recruiting ➔ Recruiting

Enrollment open • Fabry Disease • Genetic Disorders

A Proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients with Fabry Disease (clinicaltrials.gov) - P1/2 | N=18 | Not yet recruiting | Sponsor: GC Biopharma Corp

New P1/2 trial • Fabry Disease • Genetic Disorders

“Hanmi Pharm-GC Green Cross Fabry Disease Innovative New Drug, Superior to Existing Drugs“ [Google translation] (HIT News) - "...LA-GLA can efficiently reach podocytes by passing through the glomerular filtration barrier due to its structural advantage, unlike existing ERT treatments...In another study, repeated administration of LA-GLA to a severe Fabry disease animal model not only showed improved renal function compared to existing treatments such as agalsidase beta and pegunigalsidase alfa, but also significantly improved peripheral sensory dysfunction and histological lesions of nerve cells controlling it...In another study, repeated administration of LA-GLA to a severe Fabry disease animal model not only showed improved renal function compared to existing treatments such as agalsidase beta and pegunigalsidase alfa, but also significantly improved peripheral sensory dysfunction and histological lesions of nerve cells controlling it....Another study confirmed that switching from the existing treatment, pegunigaldase alfa, to LA-GLA effectively improved the...worsening renal function..."

Preclinical • Fabry Disease